Moberg Pharma AB (publ) Market Cap ($55.64 Million)
Market Cap & Net Worth: Moberg Pharma AB (publ) (MOB)
Moberg Pharma AB (publ) market cap. Moberg Pharma AB (publ) (ST:MOB) has a market capitalization of $55.64 Million (Skr517.01 Million) as of November 5, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #21276 globally and #392 in its home market, demonstrating a -0.72% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Moberg Pharma AB (publ)'s stock price Skr11.00 by its total outstanding shares 47000627 (47.00 Million). Also see Moberg Pharma AB (publ) (MOB) cash flow conversion for how efficiently the company converts equity into cash flow.
Moberg Pharma AB (publ) Market Cap History (2015–2026)
Moberg Pharma AB (publ) market cap history from 2015 to 2026. Data shows change from $694.97 Million to $55.64 Million (-18.62% CAGR). Check today's stock price for Moberg Pharma AB (publ) for real-time trading data and today's change.
Moberg Pharma AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Moberg Pharma AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore MOB net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.84x
Moberg Pharma AB (publ)'s market cap is 3.84 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $600.21 Million | $334.30 Million | $32.67 Million | 1.80x | 18.37x |
| 2017 | $291.68 Million | $439.03 Million | $11.16 Million | 0.66x | 26.14x |
| 2018 | $452.79 Million | $439.04 Million | $19.84 Million | 1.03x | 22.82x |
| 2019 | $452.02 Million | $30.82 Million | $7.96 Million | 14.66x | 56.79x |
| 2020 | $203.47 Million | $33.66 Million | -$19.03 Million | 6.05x | N/A |
| 2021 | $174.84 Million | $209.68 Million | -$16.22 Million | 0.83x | N/A |
| 2022 | $78.23 Million | $207.00K | -$15.71 Million | 377.93x | N/A |
| 2023 | $76.88 Million | $273.15 Million | -$21.09 Million | 0.28x | N/A |
| 2024 | $51.44 Million | $9.81 Million | -$255.11 Million | 5.24x | N/A |
| 2025 | $51.95 Million | $13.54 Million | -$27.24 Million | 3.84x | N/A |
Competitor Companies of MOB by Market Capitalization
Companies near Moberg Pharma AB (publ) in the global market cap rankings as of November 5, 2026. Also see Moberg Pharma AB (publ) (MOB) total assets for a full breakdown of the balance sheet.
Key companies related to Moberg Pharma AB (publ) by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Moberg Pharma AB (publ) (2015–2026)
Market capitalization of Moberg Pharma AB (publ) from 2015 to today. Between 2015 and today, Moberg Pharma AB (publ)'s market cap moved from $694.97 Million to $ 55.64 Million, with a yearly change of -18.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr55.64 Million | +7.11% |
| 2025 | Skr51.95 Million | +0.98% |
| 2024 | Skr51.44 Million | -33.09% |
| 2023 | Skr76.88 Million | -1.72% |
| 2022 | Skr78.23 Million | -55.26% |
| 2021 | Skr174.84 Million | -14.07% |
| 2020 | Skr203.47 Million | -54.99% |
| 2019 | Skr452.02 Million | -0.17% |
| 2018 | Skr452.79 Million | +55.23% |
| 2017 | Skr291.68 Million | -51.40% |
| 2016 | Skr600.21 Million | -13.64% |
| 2015 | Skr694.97 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Moberg Pharma AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $55.64 Million USD |
| MoneyControl | $55.64 Million USD |
| MarketWatch | $55.64 Million USD |
| marketcap.company | $55.64 Million USD |
| Reuters | $55.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.